Ascentage Pharma Group International reported total assets of $475.93M for the quarter ended Jun 2026, up 37.0% year over year. This balance sheet covers 5 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Dec2023 | Dec2024 | Jun2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & EquivalentsCash & Equiv. | 151.92M | 175.58M | 231.93M | 348.26M | 279.37M |
| Cash & Current Investments | 151.92M | 175.58M | 229.70M | 348.26M | 278.39M |
| Receivables - NetNet Receivables | 20.26M | 11.57M | 10.94M | 35.66M | 23.05M |
| Receivables - OtherOther Receivables | 0.92M | 0.85M | 0.21M | ||
| Receivables | 21.18M | 12.43M | 10.83M | 35.87M | 22.97M |
| Finished Goods | 1.54M | 0.54M | 1.05M | ||
| Inventory | 2.25M | 0.92M | 1.20M | 4.03M | 9.48M |
| Prepaid Assets | 12.26M | 17.15M | 22.38M | 27.15M | 26.08M |
| Current Assets | 186.69M | 205.23M | 266.45M | 415.11M | 337.99M |
| Non-Current Assets | |||||
| Property, Plant & Equipment (Net)PP&E (Net) | 160.58M | 159.21M | 143.73M | ||
| Long-Term Investments | 2.36M | 4.55M | 4.57M | 4.66M | 4.87M |
| Goodwill | 3.43M | 3.44M | 3.45M | 3.48M | 3.64M |
| Intangibles | 11.87M | 10.58M | 9.91M | 9.30M | 5.54M |
| Goodwill & Intangibles | 15.30M | 14.02M | 13.23M | 12.78M | 9.14M |
| Long-Term Deferred Tax | 8.31M | 6.16M | 4.66M | 4.51M | 2.71M |
| Other Non-Current Assets | 1.42M | 8.26M | 13.83M | 4.33M | 3.88M |
| Non-Current Assets | 160.58M | 159.21M | 158.78M | 143.73M | 139.63M |
| Assets | 347.27M | 364.44M | 421.14M | 558.84M | 475.93M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payables | 10.06M | 12.80M | 16.57M | 15.05M | 15.76M |
| Payables | 10.06M | 12.80M | 16.41M | 15.05M | 15.70M |
| Accumulated Expenses | 28.74M | 35.93M | 34.81M | 39.01M | 34.18M |
| Current Deferred Revenue | 5.33M | 5.22M | 5.23M | 5.29M | 10.25M |
| Total Current Liabilities | 217.53M | 202.03M | 252.22M | 327.13M | 277.59M |
| Non-Current Liabilities | |||||
| Non-Current Debt | 2.54M | ||||
| Non-Current Deffered Revenue | 5.05M | 3.83M | 0.92M | ||
| Minority Interest | 1.42M | 1.39M | 1.37M | ||
| Non-Current Deferred Tax LiabilityNon-Current Deferred Tax | 1.47M | 0.75M | |||
| Operating Leases | 3.15M | 4.21M | 3.13M | ||
| Other Non-Current Liabilities | 0.87M | 1.70M | |||
| Total Non-Current Liabilities | 207.72M | 163.86M | 139.02M | ||
| Total Liabilities | 337.46M | 326.27M | 370.72M | ||
| Shareholder's Equity | |||||
| Total Debt | 2.54M | ||||
| Common Equity | 9.81M | 38.17M | 188.11M | ||
| Liabilities and Shareholders Equity | 347.27M | 364.44M | 421.14M | 558.84M | 475.93M |
| Treasury Shares | -2.97M | -0.00M | -0.42M | ||
| Retained Earnings | -745.15M | -803.35M | -988.83M |